We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Valeant Reduces Prices at Walgreens, Has Similar Plans for Other Pharmacies
Sanofi, Boehringer in Asset Swap Negotiations
Kitov Eyes 2016 Submission for Arthritis-Hypertension Combo
Amgen Reacquires Product Rights on 3 Drugs From GSK
Merck Snags Approval for Bridion Read More
In what may be a first, the FDA has settled an industry suit accusing the agency of overstepping its regulatory authority over pharmaceutical promotion. Read More
India’s Natco Pharma and partner Alvogen announced Monday that they have settled a patent infringement suit filed by Gilead Sciences, Roche and Genentech over a proposed generic version of Tamiflu. Read More
With the clock about to strike midnight on 2015, CDER Director Janet Woodcock laid out a set of priorities the center will focus on in 2016, with negotiating new PDUFA and GDUFA agreements topping that list. Read More
Despite a vast, “herculean feat” to obtain clinical trial data, the effect of Merck’s lipid-lowering Vytorin on cardiovascular health was just too small — with worrying holes in data that could hinder any proof of clinical meaningfulness, FDA advisors said. Read More
Following congressional outcry, an NIH task force issued findings that show underlying problems with its now-shuttered drug compounding facilities were “widespread and longstanding,” but did not cause any direct harm to patients. Read More
Novartis reported that its Phase 2 study of CTL019, its investigational chimeric antigen receptor T cell therapy, found that 55 of 59 (93%) pediatric patients with relapsed/refractory acute lymphoblastic leukemia experienced complete remissions. Drug Industry Daily misstated the patient population. Read More
Are pharma companies getting what they pay for in terms of R&D spending? According to a new report from the Deloitte Center for Health Solutions, the answer is no. Read More